PFE
Pfizer Inc
Pfizer Inc historical holders
total: 18
Fairfax Financial Holdings Pfizer Inc transactions over time
- Total transactions:
- 8
- New positions:
- 2
- Sold out:
- 1
- Added:
- 5
- Held since:
- 2020 Q4
- Held for:
- 22 quarters
- Latest activity:
- 2026 Q1
Prem Watsa has been an institutional investor in Pfizer Inc (PFE) since 2016 Q4. According to 2026 Q1 report, Prem Watsa holds 990,900 shares with a market value of roughly $27.81M representing 1.43% of their equity portfolio. The fund/company first acquired PFE in 2016 Q4, initially purchasing 210,000 shares. Prem Watsa later completely sold out the position and reinvested in PFE again in 2020 Q4. Since the initial investment, Fairfax Financial Holdings has made 7 more transactions in this position.
Does Prem Watsa still hold PFE?
Yes, Prem Watsa continues to hold Pfizer Inc (PFE). According to their 2026 Q1 report, they maintain a position of 990,900 shares valued at approximately $27.81M, representing 1.43% of their equity portfolio.
When did Prem Watsa first invest in PFE?
Prem Watsa first invested in Pfizer Inc (PFE) in 2016 Q4 at the reported quarter-end price of $32.49 per share, acquiring 210,000 shares in their initial purchase.
What is Prem Watsa's average cost basis for PFE?
Based on historical transaction data, Prem Watsa's estimated cost basis for Pfizer Inc (PFE) is approximately $31.58 per share. This represents their average reported price* across all buy transactions.
Has Prem Watsa reinvested in PFE after selling?
Yes, Prem Watsa has shown renewed interest in Pfizer Inc (PFE). After completely selling their position, they reinitiated an investment in 2020 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $31.58
PFE transactions history by Fairfax Financial Holdings
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
1.43%
|
990,900
|
$28.07
|
$27,814,563
|
+11.22% (+100,000)
|
+0.14%
|
|
2025 Q3
|
1.10%
|
890,900
|
$25.47
|
$22,691,223
|
+36.87% (+240,000)
|
+0.3%
|
|
2024 Q4
|
1.11%
|
650,900
|
$26.54
|
$17,274,886
|
+41.22% (+190,000)
|
+0.32%
|
|
2022 Q3
|
0.52%
|
460,900
|
$43.84
|
$20,206,000
|
+14.97% (+60,000)
|
+0.07%
|
|
2021 Q1
|
0.51%
|
400,900
|
$36.23
|
$14,525,000
|
+33.23% (+100,000)
|
+0.13%
|
|
2020 Q4
|
0.49%
|
$36.81
|
new
|
|||
|
2018 Q1
|
0.00%
|
$36.25
|
-100% (-210,000)
|
|||
|
2016 Q4
|
0.58%
|
$32.49
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.